Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lyell Immunopharma, Inc.LYEL · Entity 5757 | Chief Medical Officer | September 10, 2026 | September 10, 2026 |
| Nkarta, Inc.NKTX · Entity 6346 | See Remarks | January 15, 2025 | January 17, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lyell Immunopharma, Inc.
Report date September 10, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,423 |
Reported balance
After 2026-09-10 transaction · row 1
1 source rowRow 1 · 2026-09-10 · Sale · Disposed 500 · Balance 20,423 F1: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units. F2: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $12.32 to $12.70 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
F2: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $12.32 to $12.70 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Nkarta, Inc.
Report date January 15, 2025 · Filed January 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 190,955 |
Reported balance
After 2025-01-15 transaction · row 1
1 source rowRow 1 · 2025-01-15 · Sale · Disposed 8,638 · Balance 190,955 F1: Represents shares sold as required by the applicable award terms to satisfy tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units and does not represent a discretionary transaction by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold as required by the applicable award terms to satisfy tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units and does not represent a discretionary transaction by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2026 Filed Sep 10, 2026 23:37 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | SaleCommon Stock | 500 | $12.70 | $6,350.00 |
DisclosureSEC source: 0001959742-26-000003 · form4-09102026_110937.xml · nonDerivative · entry 1 Shook David · CIK 0001959742 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,423 F1 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units. F2 · price: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $12.32 to $12.70 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 20:07 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | SaleCommon Stock | 1,977 | $12.64 | $24,989.28 |
DisclosureSEC source: 0001959742-26-000002 · form4-06112026_080646.xml · nonDerivative · entry 1 Shook David · CIK 0001959742 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,923 F1 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units. F2 · balance_after: Includes 1,000 shares acquired on May 18, 2026 under the Issuer's 2021 Employee Stock Purchase Plan. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 01:58 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 50,000 | $0.00 Strike: $23.71 | $0.00 |
DisclosureSEC source: 0001959742-26-000001 · form4-02122026_010247.xml · derivative · entry 2 Shook David · CIK 0001959742 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-02-09 F1 · derivative.exercise_date: Twelve and one-half percent (12.5%) of the total number of shares of Common Stock subject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the "Vesting Commencement Date") and thereafter, an additional one fortyeighth (1/48th) of the shares will become vested and exercisable monthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month, on the last day of such month), until the option has become vested and exercisable with respect to one hundred percent (100%) of the shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting date. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 21:45 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 43,750 | $0.00 Strike: $12.47 | $0.00 |
DisclosureSEC source: 0001415889-25-016728 · form4-06112025_090645.xml · derivative · entry 2 Shook David · CIK 0001959742 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,750 Underlying: Common Stock · 43,750 shares Expires 2035-06-08 F2 · derivative.exercise_date: 25% of the option shares will vest on June 9, 2026, with the remaining option shares to vest in equal monthly installments over the following thirty-six months, subject to the reporting person providing service through the applicable vesting date. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 21:45 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantCommon Stock | 21,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-016728 · form4-06112025_090645.xml · nonDerivative · entry 1 Shook David · CIK 0001959742 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,900 F1 · shares: Represents restricted stock units granted under the Issuer's 2021 Equity Incentive Plan ("RSUs"). 25% of the total shares subject to the RSUs will vest on June 9, 2026, and an additional 1/16th of the total shares subject to the RSUs per quarter thereafter, subject to the reporting person providing service through the applicable vesting date. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 22:37 UTC | Nkarta, Inc. NKTX · Entity 6346 | SaleCommon Stock | 8,638 | $2.20 | $19,003.60 |
DisclosureSEC source: 0000950170-25-006829 · ownership.xml · nonDerivative · entry 1 Shook David · CIK 0001959742 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,955 F1 · shares: Represents shares sold as required by the applicable award terms to satisfy tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:06 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 117,500 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0000950170-25-002835 · ownership.xml · derivative · entry 2 Shook David · CIK 0001959742 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,500 Underlying: Common Stock · 117,500 shares Expires 2035-01-02 F3 · derivative.exercise_date: This option is scheduled to vest and become exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 14, 2025. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:06 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantCommon Stock | 59,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-002835 · ownership.xml · nonDerivative · entry 1 Shook David · CIK 0001959742 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,593 F1 · shares: Represents Restricted Stock Units ("RSUs") which vest in four equal annual installments beginning on January 14, 2026. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. F2 · balance_after: Includes 2,000 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on November 30, 2024. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:30 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantCommon Stock | 1,352 | $5.11 | $6,908.72 |
DisclosureSEC source: 0000950170-24-100209 · ownership.xml · nonDerivative · entry 1 Shook David · CIK 0001959742 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,593 F1 · shares: Represents shares sold to satisfy tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units and does not represent a discretionary transaction by the Reporting Person. F2 · balance_after: Includes 2,000 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on May 31, 2024. Read SEC document |
| July 15, 2024 Filed Jul 31, 2024 20:45 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0000950170-24-088659 · ownership.xml · derivative · entry 2 Shook David · CIK 0001959742 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-07-14 F1 · date: This transaction is inadvertently filed late due to an administrative error. F3 · derivative.exercise_date: This option is scheduled to vest and become exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following July 15, 2024. Read SEC document |
| July 15, 2024 Filed Jul 31, 2024 20:45 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantCommon Stock | 23,421 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-088659 · ownership.xml · nonDerivative · entry 1 Shook David · CIK 0001959742 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,945 F1 · date: This transaction is inadvertently filed late due to an administrative error. F2 · shares: Represents Restricted Stock Units ("RSUs") which vest in four equal annual installments beginning on August 20, 2025. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 21:03 UTC | Nkarta, Inc. NKTX · Entity 6346 | SaleCommon Stock | 456 | $5.60 | $2,553.60 |
DisclosureSEC source: 0000950170-24-075730 · ownership.xml · nonDerivative · entry 1 Shook David · CIK 0001959742 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,524 F1 · shares: Represents shares sold as required by the applicable award terms to satisfy tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units and does not represent a discretionary transaction by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $5.59 to $5.60. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 21:45 UTC | Nkarta, Inc. NKTX · Entity 6346 | SaleCommon Stock | 3,552 | $8.74 | $31,044.48 |
DisclosureSEC source: 0000950170-24-005431 · ownership.xml · nonDerivative · entry 1 Shook David · CIK 0001959742 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,980 F1 · shares: Represents shares sold to satisfy tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units and does not represent a discretionary transaction by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $8.74 to $8.96. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 21:50 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 112,500 | $0.00 Strike: $6.01 | $0.00 |
DisclosureSEC source: 0001209191-24-001165 · doc4.xml · derivative · entry 2 Shook David · CIK 0001959742 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2034-01-03 F3 · derivative.exercise_date: This option is scheduled to vest and become exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 14, 2024. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 21:50 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantCommon Stock | 56,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001165 · doc4.xml · nonDerivative · entry 1 Shook David · CIK 0001959742 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,532 F1 · shares: Represents Restricted Stock Units ("RSUs") which vest in four equal annual installments beginning on January 14, 2025. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. F2 · balance_after: Includes 2,000 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on November 30, 2023. Read SEC document |
| August 21, 2023 Filed Aug 23, 2023 20:11 UTC | Nkarta, Inc. NKTX · Entity 6346 | SaleCommon Stock | 1,331 | $1.83 | $2,435.73 |
DisclosureSEC source: 0001209191-23-047037 · doc4.xml · nonDerivative · entry 1 Shook David · CIK 0001959742 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,532 F1 · shares: Represents shares sold to satisfy tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| July 01, 2023 Filed Jul 5, 2023 20:06 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 208,000 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-23-040969 · doc4.xml · derivative · entry 1 Shook David · CIK 0001959742 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,000 Underlying: Common Stock · 208,000 shares Expires 2033-06-30 F1 · derivative.exercise_date: This option is scheduled to vest and become exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following July 1, 2023. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 20:22 UTC | Nkarta, Inc. NKTX · Entity 6346 | SaleCommon Stock | 439 | $4.85 | $2,129.15 |
DisclosureSEC source: 0001209191-23-039056 · doc4.xml · nonDerivative · entry 1 Shook David · CIK 0001959742 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,863 F1 · shares: Represents shares sold to satisfy tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units and does not represent a discretionary transaction by the Reporting Person. F2 · balance_after: Includes 2,000 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on May 31, 2023. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 00:05 UTC | Nkarta, Inc. NKTX · Entity 6346 | SaleCommon Stock | 175 | $5.49 | $960.75 |
DisclosureSEC source: 0001209191-23-003855 · doc4.xml · nonDerivative · entry 2 Shook David · CIK 0001959742 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,302 F2 · shares: Represents shares sold to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a discretionary transaction by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $5.49 to $5.56. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 13, 2023 Filed Jan 19, 2023 00:05 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $5.57 | $0.00 |
DisclosureSEC source: 0001209191-23-003855 · doc4.xml · derivative · entry 3 Shook David · CIK 0001959742 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-01-12 F4 · derivative.exercise_date: This option is scheduled to vest and become exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 14, 2023. Read SEC document |
| January 13, 2023 Filed Jan 19, 2023 00:05 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-003855 · doc4.xml · nonDerivative · entry 1 Shook David · CIK 0001959742 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,477 F1 · shares: Represents Restricted Stock Units ("RSUs") which vest in four equal annual installments beginning on January 14, 2024. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.